{"id":"https://openalex.org/W2069274376","doi":"https://doi.org/10.1097/cji.0b013e31821ca6ce","title":"PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine","display_name":"PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine","publication_year":2011,"publication_date":"2011-05-14","ids":{"openalex":"https://openalex.org/W2069274376","doi":"https://doi.org/10.1097/cji.0b013e31821ca6ce","mag":"2069274376","pmid":"https://pubmed.ncbi.nlm.nih.gov/21577144","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3142955"},"language":"en","primary_location":{"id":"doi:10.1097/cji.0b013e31821ca6ce","doi":"https://doi.org/10.1097/cji.0b013e31821ca6ce","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cji.0b013e31821ca6ce","pdf_url":null,"source":{"id":"https://openalex.org/S177451610","display_name":"Journal of Immunotherapy","issn_l":"1524-9557","issn":["1524-9557","1537-4513"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Immunotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3142955","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054346063","display_name":"Jacalyn M. Rosenblatt","orcid":"https://orcid.org/0000-0001-5582-8161","observed_orcids":["https://orcid.org/0000-0001-5582-8161"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jacalyn Rosenblatt","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. jrosenb1@bidmc.harvard.edu","Beth Israel Deaconess Medical Center","Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. jrosenb1@bidmc.harvard.edu","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060510354","display_name":"Brett E. Glotzbecker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Brett Glotzbecker","raw_affiliation_strings":["Beth Israel Deaconess Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108207930","display_name":"Heidi Mills","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Heidi Mills","raw_affiliation_strings":["Beth Israel Deaconess Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072612101","display_name":"Baldev Vasir","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Baldev Vasir","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079582306","display_name":"Dimitrios Tzachanis","orcid":"https://orcid.org/0000-0003-4515-4428","observed_orcids":["https://orcid.org/0000-0003-4515-4428"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dimitrios Tzachanis","raw_affiliation_strings":["Beth Israel Deaconess Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112222630","display_name":"James D. Levine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James D. Levine","raw_affiliation_strings":["Beth Israel Deaconess Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028590331","display_name":"Robin Joyce","orcid":"https://orcid.org/0000-0002-7251-8082","observed_orcids":["https://orcid.org/0000-0002-7251-8082"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robin M. Joyce","raw_affiliation_strings":["Beth Israel Deaconess Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088700296","display_name":"Kerry Wellenstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kerry Wellenstein","raw_affiliation_strings":["Beth Israel Deaconess Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071592702","display_name":"Whitney Keefe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Whitney Keefe","raw_affiliation_strings":["Beth Israel Deaconess Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049126005","display_name":"Michael Schickler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092199","display_name":"CureTech (Israel)","ror":"https://ror.org/01cd7k542","country_code":"IL","type":"company","lineage":["https://openalex.org/I4210092199"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Michael Schickler","raw_affiliation_strings":["CureTech, Ltd, Yavne, Israel","Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CureTech, Ltd, Yavne, Israel","institution_ids":["https://openalex.org/I4210092199"]},{"raw_affiliation_string":"Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045699031","display_name":"Rinat Rotem\u2010Yehudar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092199","display_name":"CureTech (Israel)","ror":"https://ror.org/01cd7k542","country_code":"IL","type":"company","lineage":["https://openalex.org/I4210092199"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Rinat Rotem-Yehudar","raw_affiliation_strings":["CureTech, Ltd, Yavne, Israel","Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CureTech, Ltd, Yavne, Israel","institution_ids":["https://openalex.org/I4210092199"]},{"raw_affiliation_string":"Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067054634","display_name":"Donald W. Kufe","orcid":"https://orcid.org/0000-0001-5743-8888","observed_orcids":["https://orcid.org/0000-0001-5743-8888"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald Kufe","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052641327","display_name":"David Avigan","orcid":"https://orcid.org/0000-0003-4624-6017","observed_orcids":["https://orcid.org/0000-0003-4624-6017"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David Avigan","raw_affiliation_strings":["Beth Israel Deaconess Medical Center","Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Michael Schickler, PhD and Rinat Rotem-Yehudar, PhD are employees of CureTech, Ltd., which provided CT-011. Jacalyn Rosenblatt, MD and David Avigan, MD received research funding from CureTech, Ltd. All other authors have declared there are no conflicts of interest to disclose","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5028590331","https://openalex.org/A5052641327","https://openalex.org/A5054346063","https://openalex.org/A5060510354","https://openalex.org/A5071592702","https://openalex.org/A5079582306","https://openalex.org/A5088700296","https://openalex.org/A5108207930","https://openalex.org/A5112222630"],"corresponding_institution_ids":["https://openalex.org/I1316535847"],"apc_list":null,"apc_paid":null,"fwci":10.4599,"has_fulltext":false,"cited_by_count":283,"citation_normalized_percentile":{"value":0.98855792,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"34","issue":"5","first_page":"409","last_page":"418"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.7685999870300293,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.7685999870300293,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.22419999539852142,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.9779999852180481},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9919999837875366},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.8109999895095825},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9430000185966492},{"id":"https://openalex.org/keywords/t-cell-polarization","display_name":"T cell polarization","score":0.7620000243186951},{"id":"https://openalex.org/keywords/th1-th2-cytokines","display_name":"Th1/Th2 cytokines","score":0.9459999799728394},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tumor-immunosuppression","display_name":"tumor immunosuppression","score":0.7940000295639038}],"concepts":[{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.592748761177063},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5711299180984497},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5135831832885742},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5042990446090698},{"id":"https://openalex.org/C2778170410","wikidata":"https://www.wikidata.org/wiki/Q506253","display_name":"Dendritic cell","level":3,"score":0.48427814245224},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.47832489013671875},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.47432205080986023},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.44173863530158997},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.3341643214225769},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2634774446487427},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000888","descriptor_name":"Antibodies, Anti-Idiotypic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002459","descriptor_name":"Cell Fusion","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003602","descriptor_name":"Cytotoxicity, Immunologic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003713","descriptor_name":"Dendritic Cells","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D003713","descriptor_name":"Dendritic Cells","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003713","descriptor_name":"Dendritic Cells","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008213","descriptor_name":"Lymphocyte Activation","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D013602","descriptor_name":"T-Lymphocytes, Cytotoxic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D014182","descriptor_name":"Transplantation, Autologous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015703","descriptor_name":"Antigens, CD","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015703","descriptor_name":"Antigens, CD","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D015703","descriptor_name":"Antigens, CD","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019496","descriptor_name":"Cancer Vaccines","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D019496","descriptor_name":"Cancer Vaccines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D050378","descriptor_name":"T-Lymphocytes, Regulatory","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D051017","descriptor_name":"Apoptosis Regulatory Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D051017","descriptor_name":"Apoptosis Regulatory Proteins","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D051017","descriptor_name":"Apoptosis Regulatory Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D058408","descriptor_name":"Th1-Th2 Balance","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1097/cji.0b013e31821ca6ce","doi":"https://doi.org/10.1097/cji.0b013e31821ca6ce","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cji.0b013e31821ca6ce","pdf_url":null,"source":{"id":"https://openalex.org/S177451610","display_name":"Journal of Immunotherapy","issn_l":"1524-9557","issn":["1524-9557","1537-4513"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Immunotherapy","raw_type":"journal-article"},{"id":"pmid:21577144","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21577144","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of immunotherapy (Hagerstown, Md. : 1997)","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:2369834","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3142955","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3142955","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3142955","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"J Immunother","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:2369834","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3142955","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3549977710","display_name":"Host-tumor cell interaction in myeloma: therapeutic applications","funder_award_id":"5p01ca078378-15","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G4680808690","display_name":null,"funder_award_id":"P01-CA078378","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G4933731489","display_name":"SPORE in Multiple Myeloma","funder_award_id":"P50CA100707","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G5276536440","display_name":"Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications","funder_award_id":"R01CA050947","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000867162","display_name":"Integrative Oncogenomics of Multiple Myeloma","funder_award_id":"P01CA155258","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000897310","display_name":"Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology","funder_award_id":"K12CA087723","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":52,"referenced_works":["https://openalex.org/W1491508553","https://openalex.org/W1560277370","https://openalex.org/W1605269473","https://openalex.org/W1661544713","https://openalex.org/W1697880118","https://openalex.org/W1707184873","https://openalex.org/W1769456965","https://openalex.org/W1796792338","https://openalex.org/W1964416857","https://openalex.org/W1967333342","https://openalex.org/W1969349875","https://openalex.org/W1970622521","https://openalex.org/W1976269164","https://openalex.org/W1978436252","https://openalex.org/W1978721974","https://openalex.org/W1986411954","https://openalex.org/W1990779902","https://openalex.org/W1991254329","https://openalex.org/W1993617345","https://openalex.org/W1994238092","https://openalex.org/W2016789384","https://openalex.org/W2016983859","https://openalex.org/W2021588881","https://openalex.org/W2022580424","https://openalex.org/W2035852466","https://openalex.org/W2050302729","https://openalex.org/W2056535502","https://openalex.org/W2060656939","https://openalex.org/W2063221670","https://openalex.org/W2063264144","https://openalex.org/W2075820095","https://openalex.org/W2080716410","https://openalex.org/W2097855813","https://openalex.org/W2098853737","https://openalex.org/W2099699832","https://openalex.org/W2118471749","https://openalex.org/W2130207101","https://openalex.org/W2130826590","https://openalex.org/W2136313650","https://openalex.org/W2140875987","https://openalex.org/W2144953100","https://openalex.org/W2147579197","https://openalex.org/W2155464214","https://openalex.org/W2158840473","https://openalex.org/W2160117150","https://openalex.org/W2161558877","https://openalex.org/W2163804741","https://openalex.org/W2167798268","https://openalex.org/W2169700552","https://openalex.org/W2338699203","https://openalex.org/W2532570366","https://openalex.org/W2791808262"],"related_works":["https://openalex.org/W2562841154","https://openalex.org/W1523431097","https://openalex.org/W4246516219","https://openalex.org/W1970041557","https://openalex.org/W3039760757","https://openalex.org/W2955775384","https://openalex.org/W2576422933","https://openalex.org/W2002583406","https://openalex.org/W2588042509","https://openalex.org/W2061829855"],"abstract_inverted_index":{"We":[0,112],"have":[1,34],"developed":[2],"a":[3,73,159],"cancer":[4],"vaccine":[5],"in":[6,17,23,109,151,158,173],"which":[7],"autologous":[8,99],"tumor":[9,21],"is":[10,48,93,171],"fused":[11],"with":[12,72,90,145,178],"dendritic":[13],"cells":[14,64,86,154,175],"(DCs)":[15],"resulting":[16],"the":[18,24,114,134],"presentation":[19],"of":[20,26,76,103,116,128,176],"antigens":[22],"context":[25],"DC-mediated":[27],"costimulation.":[28],"In":[29,57,164],"clinical":[30],"trials,":[31],"immunologic":[32],"responses":[33,38,187],"been":[35],"observed,":[36],"however":[37],"may":[39],"be":[40],"muted":[41],"by":[42],"inhibitory":[43],"pathways.":[44],"The":[45],"PD1/PDL1":[46],"pathway":[47],"an":[49,130,139],"important":[50],"element":[51],"contributing":[52],"to":[53,95,106,122],"tumor-mediated":[54],"immune":[55],"suppression.":[56],"this":[58],"study,":[59],"we":[60,166],"demonstrate":[61,167],"that":[62,97,168,182],"myeloma":[63],"and":[65,155,181],"DC/tumor":[66,123,189],"fusions":[67,124],"strongly":[68],"express":[69],"PD-L1.":[70],"Compared":[71],"control":[74],"population":[75],"normal":[77,110],"volunteers,":[78],"increased":[79,172],"PD-1":[80,104,117,169],"expression":[81,102,170],"was":[82,162],"observed":[83],"on":[84,119],"T":[85,153,174],"isolated":[87],"from":[88],"patients":[89,177],"myeloma.":[91],"It":[92],"interesting":[94],"note":[96],"after":[98,188],"transplantation,":[100],"T-cell":[101,120,136,186],"returned":[105],"levels":[107],"seen":[108],"controls.":[111],"examined":[113],"effect":[115],"blockade":[118],"response":[121],"ex":[125],"vivo.":[126],"Presence":[127],"CT-011,":[129],"anti-PD1":[131],"antibody,":[132],"promoted":[133],"vaccine-induced":[135],"polarization":[137],"towards":[138],"activated":[140,185],"phenotype":[141],"expressing":[142],"Th1":[143],"compared":[144],"Th2":[146],"cytokines.":[147],"A":[148],"concomitant":[149],"decrease":[150],"regulatory":[152],"enhanced":[156],"killing":[157],"cytotoxicity":[160],"assay":[161],"observed.":[163],"summary,":[165],"active":[179],"myeloma,":[180],"CT-011":[183],"enhances":[184],"fusion":[190],"stimulation.":[191]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":24},{"year":2020,"cited_by_count":21},{"year":2019,"cited_by_count":19},{"year":2018,"cited_by_count":23},{"year":2017,"cited_by_count":22},{"year":2016,"cited_by_count":25},{"year":2015,"cited_by_count":37},{"year":2014,"cited_by_count":26},{"year":2013,"cited_by_count":24},{"year":2012,"cited_by_count":21}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}